Durvalumab is a monoclonal antibody for PD-L1, with activity in various tumor types such as urothelial cancer, non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, and gastroesophageal cancer, which can be combined with trastuzumab in treating HER2-positive BC [56]. This evidence concerns the gene ERBB2 and breast cancer.